Pharaoh Neuro, Inc.

Pharaoh Neuro, Inc. develops the Neurapheresis™ platform, an investigational extracorporeal cerebrospinal fluid (CSF) filtration therapy designed to remove foreign constituents, pathogens, and blood degradation products from the CSF in neurocritical patients. The company, founded in 2017 as a collaboration between Minnetronix Neuro and Duke University Medical Center, focuses on restoring CSF balance to protect brain health and improve outcomes in patients with acute neurological conditions. Current clinical initiatives include subarachnoid hemorrhage (SAH), cryptococcal meningitis, and leptomeningeal carcinomatosis. The Neurapheresis™ system operates via spinal catheter extension, offering precision management of intracranial pressure and metabolic waste clearance in the neurocritical care setting. The device is currently in clinical investigation under FDA Investigational Device Exemption (IDE) and has not yet received FDA clearance or approval for commercial distribution in the United States.